FP
Thanks for the reply. Regards that holder having more invested in IMU, maybe they're sitting on a mountain of options elsewhere and don't need to hold. It's hard to judge someone's holding without knowing personal circumstances and how they weigh up risk\reward.
For now, I just hope IMU can exit the 1b with reputation enhanced. Safety, dosage and efficacy - it's not a primary outcome, but if they've found the best dosage and the P2 is also in conjunction with SOC then it seems kind of hopeful to expect the P2 to magically start showing efficacy if there's no indication here.
Swimming against the tide here, I don't feel the market cap is being held back through lack of publicity or traders or lack of understanding. I think it's an indication of the risk associated with any biotech that has yet to show clinical efficacy.
cheers
Add to My Watchlist
What is My Watchlist?
